24 min listen
Unraveling Alzheimer's disease treatments and a look ahead
FromThe Top Line
ratings:
Length:
29 minutes
Released:
Oct 13, 2023
Format:
Podcast episode
Description
In this episode of "The Top Line," Fierce Biotech's Annalee Armstrong engages in a conversation with Howard Fillit, M.D., an expert in the field of Alzheimer's research and the co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation.
They delve into the pioneering work being done in Alzheimer's research, discuss the latest breakthroughs, and explore the ongoing efforts to combat this complex disease.
To learn more about the topics in this episode:
With full Alzheimer's approval in hand, Eisai and Biogen kick off Leqembi's launch in earnest
Eisai, Biogen's Leqembi may face rollout hurdles now, but experts still like the Alzheimer's drug
Experimental Alzheimer's molecule improves cognition in mice by tamping down on inflammation
Voyager Therapeutics adds anti-amyloid gene therapy to Alzheimer's pipeline
Acumen's stock surges as early Alzheimer's data suggest next-gen Leqembi rival is active
See omnystudio.com/listener for privacy information.
They delve into the pioneering work being done in Alzheimer's research, discuss the latest breakthroughs, and explore the ongoing efforts to combat this complex disease.
To learn more about the topics in this episode:
With full Alzheimer's approval in hand, Eisai and Biogen kick off Leqembi's launch in earnest
Eisai, Biogen's Leqembi may face rollout hurdles now, but experts still like the Alzheimer's drug
Experimental Alzheimer's molecule improves cognition in mice by tamping down on inflammation
Voyager Therapeutics adds anti-amyloid gene therapy to Alzheimer's pipeline
Acumen's stock surges as early Alzheimer's data suggest next-gen Leqembi rival is active
See omnystudio.com/listener for privacy information.
Released:
Oct 13, 2023
Format:
Podcast episode
Titles in the series (99)
July 1st, 2022 by The Top Line